Press Releases Items Per Page 102550 Year None20242023202220212020201920182017201620152014 08-26-2024 Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% 08-13-2024 Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6% 08-12-2024 Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update 08-05-2024 Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024 07-19-2024 Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule 06-27-2024 Daré Bioscience Announces Reverse Stock Split 06-24-2024 Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder 05-14-2024 Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update 05-07-2024 Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024 05-02-2024 Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 20
08-26-2024 Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Safety Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
08-13-2024 Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
08-05-2024 Daré Bioscience to Host Second Quarter 2024 Financial Results and Company Update Conference Call and Webcast on August 12, 2024
06-24-2024 Daré Bioscience Announces Publication in Obstetrics & Gynecology of Phase 2b Study Efficacy Results of Topical Sildenafil Cream, 3.6% for the Treatment of Female Sexual Arousal Disorder
05-07-2024 Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
